174 related articles for article (PubMed ID: 34998394)
1. Cost analysis of acute care resource utilization among individuals with sickle cell disease in a middle-income country.
Lobo C; Moura P; Fidlarczyk D; Duran J; Barbosa R; Oliveira T; do Nascimento EM; Bhakta N; Hankins JS
BMC Health Serv Res; 2022 Jan; 22(1):42. PubMed ID: 34998394
[TBL] [Abstract][Full Text] [Related]
2. Hydroxyurea (hydroxycarbamide) for sickle cell disease.
Rankine-Mullings AE; Nevitt SJ
Cochrane Database Syst Rev; 2022 Sep; 9(9):CD002202. PubMed ID: 36047926
[TBL] [Abstract][Full Text] [Related]
3. Hydroxyurea (hydroxycarbamide) for sickle cell disease.
Nevitt SJ; Jones AP; Howard J
Cochrane Database Syst Rev; 2017 Apr; 4(4):CD002202. PubMed ID: 28426137
[TBL] [Abstract][Full Text] [Related]
4. Impact of adherence to hydroxyurea on health outcomes among patients with sickle cell disease.
Kang HA; Barner JC; Lawson KA; Rascati K; Mignacca RC
Am J Hematol; 2023 Jan; 98(1):90-101. PubMed ID: 36251408
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of hydroxyurea in reducing the frequency of pain episodes and hospitalization in pediatric sickle cell disease.
Stallworth JR; Jerrell JM; Tripathi A
Am J Hematol; 2010 Oct; 85(10):795-7. PubMed ID: 20645429
[TBL] [Abstract][Full Text] [Related]
6. The association between hydroxyurea adherence and opioid utilization among Texas Medicaid enrollees with sickle cell disease.
Kang HA; Barner JC
J Manag Care Spec Pharm; 2020 Nov; 26(11):1412-1422. PubMed ID: 33119448
[No Abstract] [Full Text] [Related]
7. Adherence to hydroxyurea and clinical outcomes among children with sickle cell anemia.
Reeves SL; Dombkowski KJ; Peng HK; Phan H; Kolenic G; Creary SE; Madden B; Lisabeth LD
Pediatr Blood Cancer; 2023 Jul; 70(7):e30332. PubMed ID: 37046404
[TBL] [Abstract][Full Text] [Related]
8. Acute care utilization in pediatric sickle cell disease and sickle cell trait in the USA: prevalence, temporal trends, and cost.
Peterson EE; Salemi JL; Dongarwar D; Salihu HM
Eur J Pediatr; 2020 Nov; 179(11):1701-1710. PubMed ID: 32394268
[TBL] [Abstract][Full Text] [Related]
9. Impact of Medicaid expansion on access and healthcare among individuals with sickle cell disease.
Kayle M; Valle J; Paulukonis S; Holl JL; Tanabe P; French DD; Garg R; Liem RI; Badawy SM; Treadwell MJ
Pediatr Blood Cancer; 2020 May; 67(5):e28152. PubMed ID: 32147964
[TBL] [Abstract][Full Text] [Related]
10. Chronic Administration of Hydroxyurea (HU) Benefits Caucasian Patients with Sickle-Beta Thalassemia.
Di Maggio R; Hsieh MM; Zhao X; Calvaruso G; Rigano P; Renda D; Tisdale JF; Maggio A
Int J Mol Sci; 2018 Feb; 19(3):. PubMed ID: 29495591
[TBL] [Abstract][Full Text] [Related]
11. Hydroxyurea adherence and associated outcomes among Medicaid enrollees with sickle cell disease.
Candrilli SD; O'Brien SH; Ware RE; Nahata MC; Seiber EE; Balkrishnan R
Am J Hematol; 2011 Mar; 86(3):273-7. PubMed ID: 21328441
[TBL] [Abstract][Full Text] [Related]
12. Higher hydroxyurea adherence among young adults with sickle cell disease compared to children and adolescents.
Reddy PS; Cai SW; Barrera L; King K; Badawy SM
Ann Med; 2022 Dec; 54(1):683-693. PubMed ID: 35234095
[TBL] [Abstract][Full Text] [Related]
13. Treatment patterns and economic burden of sickle-cell disease patients prescribed hydroxyurea: a retrospective claims-based study.
Shah N; Bhor M; Xie L; Halloway R; Arcona S; Paulose J; Yuce H
Health Qual Life Outcomes; 2019 Oct; 17(1):155. PubMed ID: 31619251
[TBL] [Abstract][Full Text] [Related]
14. Sickle-Cell Disease Co-Management, Health Care Utilization, and Hydroxyurea Use.
Crego N; Douglas C; Bonnabeau E; Earls M; Eason K; Merwin E; Rains G; Tanabe P; Shah N
J Am Board Fam Med; 2020; 33(1):91-105. PubMed ID: 31907250
[TBL] [Abstract][Full Text] [Related]
15. Age-Related Emergency Department Reliance in Patients with Sickle Cell Disease.
Blinder MA; Duh MS; Sasane M; Trahey A; Paley C; Vekeman F
J Emerg Med; 2015 Oct; 49(4):513-522.e1. PubMed ID: 25910824
[TBL] [Abstract][Full Text] [Related]
16. Adherence to iron chelation therapy and associated healthcare resource utilization and costs in Medicaid patients with sickle cell disease and thalassemia.
Vekeman F; Sasane M; Cheng WY; Ramanakumar AV; Fortier J; Qiu Y; Duh MS; Paley C; Adams-Graves P
J Med Econ; 2016; 19(3):292-303. PubMed ID: 26618853
[TBL] [Abstract][Full Text] [Related]
17. Hydroxyurea Use for Sickle Cell Disease Among Medicaid-Enrolled Children.
Brousseau DC; Richardson T; Hall M; Ellison AM; Shah SS; Raphael JL; Bundy DG; Arnold S
Pediatrics; 2019 Jul; 144(1):. PubMed ID: 31227564
[TBL] [Abstract][Full Text] [Related]
18. Adherence to hydroxyurea, health-related quality of life domains, and patients' perceptions of sickle cell disease and hydroxyurea: a cross-sectional study in adolescents and young adults.
Badawy SM; Thompson AA; Lai JS; Penedo FJ; Rychlik K; Liem RI
Health Qual Life Outcomes; 2017 Jul; 15(1):136. PubMed ID: 28679417
[TBL] [Abstract][Full Text] [Related]
19. Neurocognitive functioning in preschool children with sickle cell disease.
Heitzer AM; Cohen DL; Okhomina VI; Trpchevska A; Potter B; Longoria J; Porter JS; Estepp JH; King A; Henley M; Kang G; Hankins JS
Pediatr Blood Cancer; 2022 Mar; 69(3):e29531. PubMed ID: 34971013
[TBL] [Abstract][Full Text] [Related]
20. Emergency department utilization for sickle cell disease in St. Vincent and the Grenadines.
Williams SA; Henson S; Trimmingham S; Newman J; Kanter J
Pan Afr Med J; 2021; 38():100. PubMed ID: 33889266
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
